This company has been acquired

NasdaqGS:ABMD Revenue, expenses and earnings (USD Millions)
Date	Revenue	Earnings	G+A Expenses	R&D Expenses
30 Sep 22	1,074	267	452	175
30 Jun 22	1,056	218	438	171
31 Mar 22	1,032	137	423	164
31 Dec 21	1,003	133	413	153
30 Sep 21	974	149	392	143
30 Jun 21	935	154	368	131
31 Mar 21	848	226	333	119
31 Dec 20	813	200	318	114
30 Sep 20	803	208	317	107
30 Jun 20	798	159	324	101
31 Mar 20	841	203	342	99
31 Dec 19	841	245	339	99
30 Sep 19	820	221	334	98
30 Jun 19	797	258	326	96
31 Mar 19	769	259	322	94
31 Dec 18	737	222	316	89
30 Sep 18	690	190	302	82
30 Jun 18	641	165	283	79
31 Mar 18	594	112	263	74
31 Dec 17	544	90	247	68
30 Sep 17	505	92	235	67
30 Jun 17	475	77	228	66
31 Mar 17	445	52	218	65
31 Dec 16	415	48	203	64
30 Sep 16	386	43	191	61
30 Jun 16	359	42	178	54
31 Mar 16	330	38	164	49
31 Dec 15	303	126	152	44

Quality Earnings: ABMD has a large one-off gain of $61.8M impacting its September 30 2022 financial results.

Growing Profit Margin: ABMD's current net profit margins (24.8%) are higher than last year (15.3%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: ABMD's earnings have grown by 5.2% per year over the past 5 years.

Accelerating Growth: ABMD's earnings growth over the past year (78.9%) exceeds its 5-year average (5.2% per year).

Earnings vs Industry: ABMD earnings growth over the past year (78.9%) exceeded the Medical Equipment industry -8.4%.

Return on Equity

High ROE: ABMD's Return on Equity (17.3%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

This company has been acquired

Abiomed Past Earnings Performance

Past criteria checks 4/6

Key information

Recent past performance updates

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Abiomed, Inc. to Report Q2, 2023 Results on Nov 01, 2022

First quarter 2023 earnings: EPS exceeds analyst expectations

Abiomed, Inc. to Report Q1, 2023 Results on Aug 04, 2022

Full year 2022 earnings: EPS exceeds analyst expectations

Abiomed, Inc. to Report Q4, 2022 Results on Apr 28, 2022

Recent updates

Johnson & Johnson (NYSE:JNJ) completed the acquisition of Abiomed, Inc. (NasdaqGS:ABMD).

Abiomed Announces United States Food and Drug Administration Approves Version of Impella ECP

Abiomed, Inc.(NasdaqGS:ABMD) dropped from FTSE All-World Index (USD)

Abiomed, Inc. Announces First Patients in the World Treated with Impella Rp Flex with Smartassist

Price target increased to US$362

Independent Director notifies of intention to sell stock

Executive VP notifies of intention to sell stock

Independent Director notifies of intention to sell stock

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Johnson & Johnson (NYSE:JNJ) entered into a definitive agreement to acquire Abiomed, Inc. (NasdaqGS:ABMD) for $17.4 billion.

Impella RP Flex with SmartAssist Receives FDA Approval to Treat Right Heart Failure

Abiomed (NASDAQ:ABMD) Has More To Do To Multiply In Value Going Forward

Abiomed, Inc. Successfully Completes All Impella Post-Approval Studies for High-Risk PCI, Cardiogenic Shock, Post-Cardiotomy Cardiogenic Shock and Right Heart Failure

The United States Food and Drug Administration Grants 510(k) Clearance for Impella Low Profile Sheath

Abiomed's Impella low profile sheath gets FDA clearance

Abiomed, Inc. to Report Q2, 2023 Results on Nov 01, 2022

Price target decreased to US$313

Abiomed: Correction Offers Good Buying Opportunity

Abiomed Announces Two Approvals from the U.S. Food and Drug Administration Related to Clinical Research of Impella Heart Pumps in Acute Myocardial Infarction Cardiogenic Shock Patients

U.S. FDA gives two approvals to Abiomed Impella heart pumps

What Does Abiomed, Inc.'s (NASDAQ:ABMD) Share Price Indicate?

Abiomed Announces Restore EF Study Shows Heart Function, Symptom Improvements for High-Risk PCI Patients Supported by Impella

First quarter 2023 earnings: EPS exceeds analyst expectations

Abiomed, Inc. (NasdaqGS:ABMD) announces an Equity Buyback for $200 million worth of its shares.

Price target decreased to US$319

Abiomed FQ1 2023 Earnings Preview

Abiomed, Inc. to Report Q1, 2023 Results on Aug 04, 2022

Returns On Capital At Abiomed (NASDAQ:ABMD) Have Stalled

Abiomed, Inc., Annual General Meeting, Aug 10, 2022

Abiomed's Profit Growth Slows On R&D, Sales Hold Strong Despite Shortages

Full year 2022 earnings: EPS exceeds analyst expectations

Abiomed, Inc. to Report Q4, 2022 Results on Apr 28, 2022

Abiomed, Inc. Announces Retirement of David Weber as Senior Vice President, Chief Operating Officer

Is Abiomed (NASDAQ:ABMD) A Risky Investment?

Independent Director recently sold US$1.2m worth of stock

Senior VP & COO exercised options and sold US$3.1m worth of stock

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Abiomed, Inc. Revises Revenue Guidance for the Fiscal Year 2022

Consensus forecasts updated

Abiomed's Less Troubled 2020 Justifies Multiple, But Medium-Term Headwinds Mean Capital Risk

Early Feasibility Study Demonstrates Successful Use of Abiomed’s preCARDIA Technology

Abiomed, Inc. Announces Regulators Grants Approvals for Impella Surgical Products

The Returns At Abiomed (NASDAQ:ABMD) Aren't Growing

These 4 Measures Indicate That Abiomed (NASDAQ:ABMD) Is Using Debt Safely

Abiomed, Inc. (NasdaqGS:ABMD) agreed to acquire all the assets and business from Sensera, Inc. for $7.5 million.

Independent Director recently sold US$5.1m worth of stock

Second quarter 2022 earnings released: EPS US$1.25 (vs US$1.38 in 2Q 2021)

Abiomed: Impella Will Continue To Drive Revenue Growth

Here's What To Make Of Abiomed's (NASDAQ:ABMD) Decelerating Rates Of Return

Independent Director notifies of intention to sell stock

Consensus forecasts updated

Chairman exercised options and sold US$8.0m worth of stock

First quarter 2022 earnings released: EPS US$1.38 (vs US$0.99 in 1Q 2021)

Abiomed: Recovery Mode Has Been Activated - Reiterate Buy Rating

At US$335, Is It Time To Put Abiomed, Inc. (NASDAQ:ABMD) On Your Watch List?

Abiomed’s Receives U.S. Food and Drug Administration Pre-Market Approval as Safe and Effective to Treat Acute Right Heart Failure for Up to 14 Days

Chairman exercised options and sold US$7.6m worth of stock

DSMB recommends Abiomed trial for heart pump in cardiogenic shock continue

Abiomed, Inc. (NasdaqGS:ABMD) acquired Precardia Inc.

Abiomed acquires preCARDIA a company targeting acute heart failure

Full year 2021 earnings released: EPS US$5.00 (vs US$4.49 in FY 2020)

Here's Why I Think Abiomed (NASDAQ:ABMD) Might Deserve Your Attention Today

Senior VP & COO exercised options and sold US$3.7m worth of stock

Boston Scientific’s new clinical trial can impact Abiomed: Raymond James

Full year 2021 earnings released: EPS US$5.00 (vs US$4.49 in FY 2020)

Abiomed, Inc. Provides Earnings Guidance for the Fiscal Year 2022

Abiomed FQ4 2021 Earnings Preview

Should You Investigate Abiomed, Inc. (NASDAQ:ABMD) At US$315?

Revenue & Expenses Breakdown
Beta